Reported $139.0M in cash and cash equivalents as of September 30, expected to fund planned operations through 2027. “Both tibulizumab studies advanced during the quarter,” said Kiran Nistala, Chief Medical Officer. “We continue to focus on disciplined study execution and patient enrollment across these important disease areas, with the aim of generating meaningful data.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZURA:
- Zura Bio initiated with a Buy at Clear Street
- Zura Bio’s Promising Phase 2 Study on Tibulizumab for Systemic Sclerosis
- Zura Bio’s Promising Phase 2 Study on Tibulizumab for Hidradenitis Suppurativa
- Zura Bio CEO Takes Medical Leave, Interim Appointed
- Zura Bio Implements Executive Severance Benefit Plan